Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors.
Seethapathy H, Street S, Strohbehn I, Lee M, Zhao SH, Rusibamayila N, Chute DF, Gao X, Michaelson MD, Rahma OE, Choueiri TK, McGregor B, Sonpavde G, Salabao C, Kaymakcalan MD, Wei X, Gupta S, Motwani S, Leaf DE, Reynolds KL, Sise ME. Seethapathy H, et al. Among authors: wei x. Eur J Cancer. 2021 Nov;157:50-58. doi: 10.1016/j.ejca.2021.07.031. Epub 2021 Sep 2. Eur J Cancer. 2021. PMID: 34482189
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK. McKay RR, et al. Among authors: wei xx. Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10. Cancer Immunol Res. 2018. PMID: 29748390 Free PMC article.
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, Choueiri TK. McGregor BA, et al. Among authors: wei xx. J Clin Oncol. 2020 Jan 1;38(1):63-70. doi: 10.1200/JCO.19.01882. Epub 2019 Nov 13. J Clin Oncol. 2020. PMID: 31721643 Free PMC article. Clinical Trial.
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ. Nassar AH, et al. Among authors: wei xx. Br J Cancer. 2020 Feb;122(4):555-563. doi: 10.1038/s41416-019-0686-0. Epub 2019 Dec 20. Br J Cancer. 2020. PMID: 31857723 Free PMC article.
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC. Abou Alaiwi S, et al. Among authors: wei x. J Immunother Cancer. 2020 Feb;8(1):e000144. doi: 10.1136/jitc-2019-000144. J Immunother Cancer. 2020. PMID: 32066646 Free PMC article.
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA, Lalani AA, Xie W, Steinharter JA, E Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, Kaymakcalan MD, Braun DA, Wei XX, Harshman LC, Bilen MA, Choueiri TK. McGregor BA, et al. Among authors: wei xx. Eur J Cancer. 2020 Aug;135:203-210. doi: 10.1016/j.ejca.2020.05.009. Epub 2020 Jun 27. Eur J Cancer. 2020. PMID: 32599410
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
Wei XX, Werner L, Teo MY, Rosenberg JE, Koshkin VS, Grivas P, Szabados B, Morrison L, Powles T, Carril-Ajuria L, Castellano D, Velho PI, Hahn NM, McKay RR, Raggi D, Necchi A, Kanesvaran R, Alerasool P, Gaines J, Galsky M, Bellmunt J, Sonpavde G. Wei XX, et al. J Urol. 2021 Feb;205(2):414-419. doi: 10.1097/JU.0000000000001371. Epub 2020 Sep 16. J Urol. 2021. PMID: 32935617 Free PMC article.
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK. McKay RR, et al. Among authors: wei x. J Clin Oncol. 2020 Dec 20;38(36):4240-4248. doi: 10.1200/JCO.20.02295. Epub 2020 Oct 27. J Clin Oncol. 2020. PMID: 33108238 Free PMC article. Clinical Trial.
16,113 results
You have reached the last available page of results. Please see the User Guide for more information.